Evaluation of Heat Shock Protein-90 as a Potential Risk Marker in Sera Women with Breast Cancer
الباحث الأول:
Addai Ali, Hanaa Addai
الباحثين الآخرين:
Safaa Mueen Hassoun, Maha Abd Alkadhim Abd, Muthana Saleh Mashkour, Rawaa Adday Ali, Mohammed Kadhim Alyaseen
المجلة:
Asian Pacific Journal of Cancer Biology
تاريخ النشر:
27 سبتمبر، 2025
مختصر البحث:
Breast cancer (BC) the second most common kind of newly diagnosed malignancy worldwide, is the most common illness among women. Heat shock protein 90 (HSP-90) plays a crucial in the growth and spread of cancer cells by maintaining the stability of …
Breast cancer (BC) the second most common kind of newly diagnosed malignancy worldwide, is the most common illness among women. Heat shock protein 90 (HSP-90) plays a crucial in the growth and spread of cancer cells by maintaining the stability of overexpressed signaling proteins. Aim of study: Evaluate serum levels of HSP-90 as potential risk markers in breast cancer patients as compared to healthy individuals.Subject and methods: The research included 180 participants. Ninety females with BC (23 stage I, 36 stage II, 24 stage III, and 7 stage IV) contrasted with 90 healthy women as a control group matched with patients in age. Serum HSP-90 was measured using the ELISA technique kits. Additionally, lipid profiles and liver enzyme were assessed. Results: Serum HSP-90 levels were significantly elevated across all stages in women with BC compared to healthy women (P < 0.001), as well as among different stages of the disease. There was an increase in serum total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in patients. In contrast, there was a decrease in serum high density lipoprotein cholesterol (HDL-C) levels compared to healthy controls. Additionally, HSP-90 showed a significant positive correlation with age, ALP, TG, TC, HDL-C, LDL-C, ALT, AST, and VLDL-C with the exception of body mass index (BMI). HSP-90 demonstrated good diagnostic efficiency in breast cancer patients, with a cut-off value for HSP-90 at 300.5 pg/mL. This marker exhibited a sensitivity of 88.9% and a specificity of 87.8% with an area under the curve (AUC) of 0.907 (95% CI: 0.86-0.954; P < 0.001). Conclusion: HSP-90 may be a biomarker for breast cancer monitoring and early detection.
